Ferric Carboxymaltose across all ages in Paediatric Gastroen
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The aim of the study was to assess the efficacy, safety and side-effect profile of ferric carboxymaltose (FCM) for correcting Iron-Deficiency Anemia (IDA) in children and adolescents in paediatric gastroenterology, hepatology, and nutrition.

This was a retrospective study of all gastroenterology patients less than 18 years who had FCM. Haematological and biochemical parameters were recorded pre-infusion, at 4 weeks, 3 months, 6 months, and 1 year post-infusion. Recognised side-effects were documented.

--66 children received FCM during this period. Data was analysed on 61 children, 5 excluded because of inadequate data. The median age at administration was 14 years (IQR 7).

--32 were boys. 26 were less than 14 years old. 7 were less than 5 years old. 17 were switched from oral iron supplements to FCM. The median dose of FCM delivered was 19 mg/kg. The median haemoglobin increased from 108 to 126 g/L at 1 month post-infusion.

--The mean cell volume also improved from 80 to 84 fL at 1 month post-infusion. 48 children corrected their anaemia after receiving FCM. 2 patients reported side-effects with skin bruising and staining.

FCM tends to be successful in correcting Iron-Deficiency Anemia (IDA) in children of all ages and across a broad spectrum of gastroenterology indications. It is successful and well tolerated in most patients, including those who are very young. Careful monitoring during infusions can help to prevent potential side effects.

Source: https://journals.lww.com/jpgn/Abstract/2021/04000/Ferric_Carboxymaltose_Across_All_Ages_in.4.aspx